Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as sigvotatug vedotin, Sigvotatug Vedotin, PF-07275315
PF-07275315 dose 1 · 1 trial · 1 indication
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Exacerbation of Chronic Obstructive Pulmonary Disease (ECOPD) are sudden worsening of respiratory symptoms that significantly worsen lung function and quality of life.
| Arm | Type | Description |
|---|---|---|
| Phase 3 Treatment Arm A | EXPERIMENTAL | - |
| Phase 2 Treatment Arm B | EXPERIMENTAL | - |
| Phase 2 Treatment Arm A | EXPERIMENTAL | - |
| Phase 3 Treatment Arm B | PLACEBO_COMPARATOR | - |
| Phase 2 Treatment Arm C | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-07275315 dose 1 | DRUG | SC injection dose 1 |
| PF-07275315-dose 2 | DRUG | SC injection dose 2 |
| Placebo | DRUG | SC injection matched |
| PF-07275315-dose 3 | DRUG | SC injection dose 3 |
Key Inclusion Criteria: * Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition). * Spirometry values (post-bronchodilator forced expiratory volume in 1 second \[FEV1\]/forced vital capac...
PF-07275315 is an investigational small molecule being studied for atopic dermatitis, non-small cell lung cancer, and asthma. It is also being evaluated in healthy volunteers and healthy participants. The drug is currently in Phase 2 clinical development for moderate-to-severe asthma.
PF-07275315 targets the cytokines IL-4, IL-13, and TSLP. These are signaling proteins involved in inflammatory and immune responses. By targeting these cytokines, the drug aims to modulate pathways relevant to conditions like asthma and atopic dermatitis.
PF-07275315 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various conditions.
PF-07275315 is in Phase 2 clinical development. It has completed Phase 1 trials in healthy participants and is currently being studied in a Phase 2 trial for moderate-to-severe asthma. The drug is investigational and has not been approved by regulatory authorities.
PF-07275315 has been studied in several clinical trials. Completed Phase 1 trials include NCT04756531, NCT05411588, and NCT06675188, which evaluated the drug in healthy participants. An ongoing Phase 2 trial, NCT06977581, is recruiting patients with moderate-to-severe asthma.
Yes, PF-07275315 is also known as sigvotatug vedotin. The drug is referred to by both names in clinical research. It is being developed by Pfizer for conditions including atopic dermatitis, non-small cell lung cancer, and asthma.